Company intelligence / Profile preview
Galderma
Zug, Switzerlandgalderma.com ↗
- Ownership
- Public · GALD
- Employees
- ~6545
- Development stage
- Other
01
Overview
Galderma is the world's largest independent global dermatology company with a portfolio spanning prescription medicine, aesthetics, and consumer care. In 2024, their monoclonal antibody Nemluvio (nemolizumab) received FDA approval for moderate-to-severe atopic dermatitis in patients 12 years and older.
- Therapeutic areas
- OncologyDermatology
- Modalities
- Prescription drugsMonoclonal antibodiesDermatological skincareInjectable aesthetics
- Industry
- Biotech
02
Drug pipeline
57 assets56 more assets in the full pipeline.
03
Partnerships
Healthcare professionalsAcademia
04
Financials
- Market cap
- $54.2B
- Total revenue
- $5.2B
- Enterprise value
- $56.1B
Beyond the preview
Go deeper on Galderma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Galderma.